Nestin regulates proliferation, migration, invasion and stemness of lung adenocarcinoma

International Journal of Oncology

Volumn 44, Issue 4, 2014, Pages 1118-1130

  Narita, Kosuke ^a   Matsuda, Yoko ^a   Seike, Masahiro ^a   Naito, Zenya ^a   Gemma, Akihiko ^a   Ishiwata, Toshiyuki ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Akt inhibitor IV; Cancer stem cell; Lung cancer; Nestin; SRY box containing protein 2

Indexed keywords

NESTIN; PROTEIN KINASE B; SMALL INTERFERING RNA; SOX2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR SOX;

ADENOCARCINOMA; AGED; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CANCER STEM CELL; CELL MOTION; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LUNG TUMOR; MALE; METABOLISM; MULTICELLULAR SPHEROID; NON SMALL CELL LUNG CANCER; PATHOLOGY; RETROSPECTIVE STUDY; RNA INTERFERENCE; TUMOR CELL CULTURE; TUMOR INVASION;

ADENOCARCINOMA; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM INVASIVENESS; NEOPLASTIC STEM CELLS; NESTIN; PROTO-ONCOGENE PROTEINS C-AKT; RETROSPECTIVE STUDIES; RNA INTERFERENCE; RNA, SMALL INTERFERING; SOXB1 TRANSCRIPTION FACTORS; SPHEROIDS, CELLULAR; TUMOR CELLS, CULTURED;

EID: 84894461291     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2278     Document Type: Article

References (59)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
2. Husain AN: Lung tumors. In: Robbins Basic Pathology. Kumar V, Abbas AK and Aster JC (eds.) Elsevier Saunders, Philadelphia, PA, pp505-510, 2013.
3. Non-small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311: 899-909, 1995.
4. Maemondo M, Inoue A, Kobayashi K, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362: 2380-2388, 2010.
5. Devesa SS, Bray F, Vizcaino AP and Parkin DM: International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer 117: 294-299, 2005.
6. Mitsudomi T, Morita S, Yatabe Y, et al: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11: 121-128, 2010.
7. Shaw AT, Kim DW, Nakagawa K, et al: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368: 2385-2394, 2013.
8. Choi YL, Soda M, Yamashita Y, et al: EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 363: 1734-1739, 2010.
9. Kobayashi S, Boggon TJ, Dayaram T, et al: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352: 786-792, 2005.
10. Engelman JA, Zejnullahu K, Mitsudomi T, et al: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043, 2007.
11. Marvin MJ, Dahlstrand J, Lendahl U and McKay RD: A rod end deletion in the intermediate filament protein nestin alters its subcellular localization in neuroepithelial cells of transgenic mice. J Cell Sci 111: 1951-1961, 1998.
12. Sjöberg G, Jiang WQ, Ringertz NR, Lendahl U and Sejersen T: Colocalization of nestin and vimentin/desmin in skeletal muscle cells demonstrated by three-dimensional fluorescence digital imaging microscopy. Exp Cell Res 214: 447-458, 1994.
13. Lendahl U, Zimmerman LB and McKay RD: CNS stem cells express a new class of intermediate filament protein. Cell 60: 585-595, 1990.
14. Esni F, Stoffers DA, Takeuchi T and Leach SD: Origin of exocrine pancreatic cells from nestin-positive precursors in developing mouse pancreas. Mech Dev 121: 15-25, 2004.
15. Ishiwata T, Teduka K, Yamamoto T, Kawahara K, Matsuda Y and Naito Z: Neuroepithelial stem cell marker nestin regulates the migration, invasion and growth of human gliomas. Oncol Rep 26: 91-99, 2011.
16. Akiyama M, Matsuda Y, Ishiwata T, Naito Z and Kawana S: Inhibition of the stem cell marker nestin reduces tumor growth and invasion of malignant melanoma. J Invest Dermatol 133: 1384-1387, 2013.
17. Kawamoto M, Ishiwata T, Cho K, et al: Nestin expression correlates with nerve and retroperitoneal tissue invasion in pancreatic cancer. Hum Pathol 40: 189-198, 2009.
18. Matsuda Y, Naito Z, Kawahara K, Nakazawa N, Korc M and Ishiwata T: Nestin is a novel target for suppressing pancreatic cancer cell migration, invasion and metastasis. Cancer Biol Ther 11: 512-523, 2011.
19. Kleeberger W, Bova GS, Nielsen ME, et al: Roles for the stem cell associated intermediate filament Nestin in prostate cancer migration and metastasis. Cancer Res 67: 9199-9206, 2007.
20. Ishiwata T, Matsuda Y and Naito Z: Nestin in gastrointestinal and other cancers: effects on cells and tumor angiogenesis. World J Gastroenterol 17: 409-418, 2011.
21. Ryuge S, Sato Y, Wang GQ, et al: Prognostic significance of nestin expression in resected non-small cell lung cancer. Chest 139: 862-869, 2011.
22. Ryuge S, Sato Y, Jiang SX, et al: Prognostic impact of nestin expression in resected large cell neuroendocrine carcinoma of the lung. Lung Cancer 77: 415-420, 2012.
23. Skarda J, Kolar Z, Janikova M, et al: Analysis of the prognostic impact of nestin expression in non-small cell lung cancer. Biomed Pap Med Fac, Univ Palacky Olomouc, Czech Repub 156: 135-142, 2012.
24. Chen Z, Wang T, Luo H, et al: Expression of nestin in lymph node metastasis and lymphangiogenesis in non-small cell lung cancer patients. Hum Pathol 41: 737-744, 2010.
25. Janikova M, Skarda J, Dziechciarkova M, et al: Identification of CD133+/nestin+ putative cancer stem cells in non-small cell lung cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 154: 321-326, 2010.
26. Takakuwa O, Maeno K, Kunii E, et al: Involvement of intermediate filament nestin in cell growth of small-cell lung cancer. Lung Cancer 81: 174-179, 2013.
27. Goldstraw P, Crowley J, Chansky K, et al: The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2: 706-714, 2007.
28. Ishiwata T, Matsuda Y, Yamamoto T, Uchida E, Korc M and Naito Z: Enhanced expression of fibroblast growth factor receptor 2 IIIc promotes human pancreatic cancer cell proliferation. Am J Pathol 180: 1928-1941, 2012.
29. Matsuda Y, Ishiwata T, Yamahatsu K, et al: Overexpressed fibroblast growth factor receptor 2 in the invasive front of colorectal cancer: a potential therapeutic target in colorectal cancer. Cancer Lett 309: 209-219, 2011.
30. Yamahatsu K, Matsuda Y, Ishiwata T, Uchida E and Naito Z: Nestin as a novel therapeutic target for pancreatic cancer via tumor angiogenesis. Int J Oncol 40: 1345-1357, 2012.
31. Matsuda Y, Hagio M, Seya T and Ishiwata T: Fibroblast growth factor receptor 2 IIIc as a therapeutic target for colorectal cancer cells. Mol Cancer Ther 11: 2010-2020, 2012.
32. Kawase R, Ishiwata T, Matsuda Y, et al: Expression of fibroblast growth factor receptor 2 IIIc in human uterine cervical intraepithelial neoplasia and cervical cancer. Int J Oncol 36: 331-340, 2010.
33. Arai K, Sakamoto R, Kubota D and Kondo T: Proteomic approach toward molecular backgrounds of drug resistance of osteosarcoma cells in spheroid culture system. Proteomics 13: 2351-2360, 2013.
34. Ushijima H and Maeda M: cAMP-dependent proteolysis of GATA-6 is linked to JNK-signaling pathway. Biochem Biophys Res Commun 423: 679-683, 2012.
35. Huang YL, Wu CM, Shi GY, et al: Nestin serves as a prosurvival determinant that is linked to the cytoprotective effect of epidermal growth factor in rat vascular smooth muscle cells. J Biochem 146: 307-315, 2009.
36. Xue XJ and Yuan XB: Nestin is essential for mitogen-stimulated proliferation of neural progenitor cells. Mol Cell Neurosci 45: 26-36, 2010.
37. Brognard J, Clark AS, Ni Y and Dennis PA: Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 61: 3986-3997, 2001.
38. Guo Y, Du J and Kwiatkowski DJ: Molecular dissection of AKT activation in lung cancer cell lines. Mol Cancer Res 11: 282-293, 2013.
39. Singh S, Trevino J, Bora-Singhal N, et al: EGFR/Src/Akt signaling modulates Sox2 expression and self-renewal of stem-like side-population cells in non-small cell lung cancer. Mol Cancer 11: 73, 2012.
40. Tanaka S, Kamachi Y, Tanouchi A, Hamada H, Jing N and Kondoh H: Interplay of SOX and POU factors in regulation of the Nestin gene in neural primordial cells. Mol Cell Biol 24: 8834-8846, 2004.
41. Dobashi Y, Kimura M, Matsubara H, Endo S, Inazawa J and Ooi A: Molecular alterations in AKT and its protein activation in human lung carcinomas. Hum Pathol 43: 2229-2240, 2012.
42. Liu K, Lin B, Zhao M, et al: The multiple roles for Sox2 in stem cell maintenance and tumorigenesis. Cell Signal 25: 1264-1271, 2013.
43. Nakatsugawa M, Takahashi A, Hirohashi Y, et al: SOX2 is over-expressed in stem-like cells of human lung adenocarcinoma and augments the tumorigenicity. Lab Invest 91: 1796-1804, 2011.
44. Sholl LM, Barletta JA, Yeap BY, Chirieac LR and Hornick JL: Sox2 protein expression is an independent poor prognostic indicator in stage I lung adenocarcinoma. Am J Surg Pathol 34: 1193-1198, 2010.
45. Noro R, Gemma A, Kosaihira S, et al: Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation. BMC Cancer 6: 277, 2006.
46. Pao W, Miller VA, Politi KA, et al: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2: e73, 2005.
47. Nolte SM, Venugopal C, McFarlane N, et al: A cancer stem cell model for studying brain metastases from primary lung cancer. J Natl Cancer Inst 105: 551-562, 2013.
48. Clarke MF, Dick JE, Dirks PB, et al: Cancer stem cells - perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 66: 9339-9344, 2006.
49. Eramo A, Lotti F, Sette G, et al: Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 15: 504-514, 2008.
50. Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer, and cancer stem cells. Nature 414: 105-111, 2001.
51. Ho MM, Ng AV, Lam S and Hung JY: Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res 67: 4827-4833, 2007.
52. Liang D and Shi Y: Aldehyde dehydrogenase-1 is a specific marker for stem cells in human lung adenocarcinoma. Med Oncol 29: 633-639, 2012.
53. Alamgeer M, Peacock CD, Matsui W, Ganju V and Watkins DN: Cancer stem cells in lung cancer: Evidence and controversies. Respirology 18: 757-764, 2013.
54. Bombí JA, Martínez A, Ramírez J, et al: Ultrastructural and molecular heterogeneity in non-small cell lung carcinomas: study of 110 cases and review of the literature. Ultrastruct Pathol 26: 211-218, 2002.
55. Kau TR, Schroeder F, Ramaswamy S, et al: A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. Cancer Cell 4: 463-476, 2003.
56. Lam EW, Francis RE and Petkovic M: FOXO transcription factors: key regulators of cell fate. Biochem Soc Trans 34: 722-726, 2006.
57. Sangodkar J, Dhawan NS, Melville H, et al: Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response. J Clin Invest 122: 2637-2651, 2012.
58. Zhang X, Yalcin S, Lee DF, et al: FOXO1 is an essential regulator of pluripotency in human embryonic stem cells. Nat Cell Biol 13: 1092-1099, 2011.
59. DeFeo-Jones D, Barnett SF, Fu S, et al: Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members. Mol Cancer Ther 4: 271-279, 2005.